Substantial basic science and clinical evidence suggests that excess tumor necrosis factor-alpha (TNF-alpha) is centrally involved in the pathogenesis of Alzheimer's disease. In addition to its ...
Please provide your email address to receive an email when new articles are posted on . Approximately 70% of patients with juvenile idiopathic arthritis who are re-treated with etanercept achieve ...
Real-world evidence shows switching between etanercept products and etanercept biosimilars preserves efficacy and safety, ...
Please provide your email address to receive an email when new articles are posted on . Etanercept and adalimumab are both impactful at improving the health of ...
The RENEWAL trial combined data that were collected in the Randomized Etanercept North American Strategy to Study Antagonism of Cytokines (RENAISSANCE) trial in North America and the Research into ...
The government of Australia’s pricing policy links the price of new medications with similar safety and efficacy, resulting in significant savings over the first 3 years after the etanercept ...
Real-world data suggest anti-TNF biosimilars for juvenile idiopathic arthritis offer comparable efficacy and safety to their brand name counterparts. As high-cost originator biologics continue to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results